Last 35 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.82 | — | — | 59.96 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 12.12 | 34.97 | 16.12 | 21.87 | 75.79 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 99.56 | 29.30 | 15.56 | 49.22 | 118.87 | 566.60 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -16.2% | -94.8% | — | -99.5% | — | +374.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 19.12 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 58.8% | 23.4% | 25.5% | 48.3% | 43.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -1324.4% | -590.8% | -444.6% | -467.3% | -1701.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -2336.5% | -1500.5% | -133.9% | 36.6% | -2433.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -309.9% | -84.7% | -43.1% | -24.5% | -51.2% | -206.8% | -413.2% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -504.8% | +59.1% | +89.6% | — | +97.5% | — | -173.2% | |
| ROA | -344.7% | -71.7% | -11.5% | 2.6% | -59.4% | -282.9% | -98.1% | -223.8% | -33.4% | -174.5% | -117.6% | -42.4% | -36.8% | -41.9% | -46.4% | -40.4% | -31.7% | -18.4% | -35.2% | -79.0% | -116.1% |
| — | +74.6% | +88.3% | +101.2% | -78.0% | -62.2% | +16.6% | -427.6% | +9.4% | -316.2% | -153.5% | -4.9% | -16.1% | -128.3% | -31.6% | +48.8% | +72.7% | -1818.7% | +93.8% | +92.1% | -38.5% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.42 | — | — | 0.02 | 0.02 | 0.06 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +5605.8% | — | — | -99.3% | — | -92.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.31 | 0.86 | 0.29 | 0.31 | 0.29 | 0.11 | 0.22 | 0.15 | 0.20 | 0.21 | 0.18 | 0.36 | 0.68 | 0.87 | 0.99 | 1.66 | 3.08 | 4.58 | 3.66 | 2.74 | 1.25 |
| — | +658.6% | +32.0% | +106.0% | +45.5% | -45.0% | +24.8% | -58.2% | -70.1% | -76.4% | -82.0% | -78.2% | -78.0% | -80.9% | -73.1% | -39.7% | +147.4% | +776.1% | +3843.4% | +4223.0% | +386.9% | |
| Quick Ratio | 0.31 | 0.86 | 0.29 | 0.31 | 0.29 | 0.11 | 0.22 | 0.15 | 0.20 | 0.21 | 0.18 | 0.36 | 0.68 | 0.87 | 0.99 | 1.66 | 3.08 | 4.58 | 3.66 | 2.74 | 1.25 |
| — | +658.6% | +32.0% | +106.0% | +45.5% | -45.0% | +24.8% | -58.2% | -70.1% | -76.4% | -82.0% | -78.2% | -78.0% | -80.9% | -73.1% | -39.7% | +147.4% | +776.1% | +3843.4% | +4563.6% | +386.9% | |
| Interest Coverage | -41.66 | -67.83 | -5.14 | 1.54 | — | — | — | — | — | -8.30 | -27.38 | -53.15 | -150.55 | — | — | — | — | — | -4481.67 | -13135.97 | -6900.89 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NRXP stock.
NRx Pharmaceuticals, Inc.'s current P/E is -3.8x. The average P/E over the last 1 quarters is 60.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
NRx Pharmaceuticals, Inc.'s current operating margin is -1324.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking NRx Pharmaceuticals, Inc.'s business trajectory between earnings reports.